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Title: Hybrid Practices in Cord Blood Banking. Rethinking the Com-
modification of Human Tissues in the Bioeconomy 
Abstract: The STS and bioethical literature on umbilical cord blood (UCB) banking now-
adays discusses the field as divided into opposite institutional arrangements, public versus 
private banking. Public banks represent a model sharing economy, private banks a market 
economy that capitalizes hopes and tissues, and new hybrid forms that are emerging. We 
challenge that this distinction is analytically valuable for understanding the various forms 
of marketization, commodification and biovalue production that mark the UCB economy. 
Our analysis of current UCB banking practices, especially hybrid one’s, and their inherent 
visions of the future, shows that hybrid UCB banking criss-crosses the different economic 
models and concepts of commodification. The private, public, hybrid distinction is thus 
inadequate for a critically analysis of the complex UCB bioeconomies. Drawing on the 
perspective of social welfare systems analysis, however, the tripartite distinction empha-
sises an important ethical and biopolitical commitment to equality in current and future 
health care. 
Introduction 
After the first successful transplantation of umbilical cord blood (UCB) in 1988 (Gluck-
man et al. 1989), the clinical use of UCB-derived stem cells for treating haematological 
malignancies, bone marrow failures and inherited metabolic disorders has increased to an 
estimated 30.000 UCB transplantations performed worldwide (Ballen, Gluckman and 
Broxmeyer 2013). In order to be used as a source of haematopoietic stem cells, UCB must 
be collected, processed and cryopreserved in biobanks. During the 1990s, national public 
UCB banks were established in increasing numbers, beginning in the US, France, the UK, 
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Germany, Italy and Spain (Gluckman 1996). Nowadays, according to Bone Marrows Do-
nor Worldwide, more than 600,000 UCB units are stored in public banks and other par-
ticipating registries (BMDW 2015). A competing sector of private or family banking 
emerged in the same period – among the first such banks were Cryo-Cell in Oldsmar, 
Florida, founded in 1989 (Cryo-Cell 2015), Cord Blood Registry in San Bruno, Califor-
nia, 1992 (Cord Blood Registry 2015), ViaCord in Boston, Massachusetts, 1993 (ViaCord 
2015), and Vita34 in Leipzig, Germany, 1997 (Vita34 2015a). They offer mother or pro-
spective parents storage of the UCB at birth for future autologous or family-related uses. 
Parent’s Guide to Cord Blood Foundation (2015) reports there are more than one million 
UCB units stored in family banks in the US alone. 
UCB banking represents an important element in the scholarly analysis of “tissue 
economies” (Waldby and Mitchell 2006), not least because scholars compare two distinct 
biobanking models: a system of public UCB banks collecting freely donated tissues that 
are distributed for use in haematological clinical applications when and where needed; 
and a sector of commercial banks selling a private storage service and thus ownership of 
the tissue. The bioethical and biomedical literature describes these banking services as 
two different economic regimes: public biobanks work in a gift or redistributive economic 
logic of public health, whereas private biobanks provide a service in a competing com-
mercial health economy, they sell the “personal UCB account” (Waldby and Mitchell 
2006). Put simply, this literature establishes two equations: public = redistributive and 
private = market economy. The UCB economies in these two institutional arrangements 
are linked to different ethical and economic regimes and seen as carrying opposite societal 
and cultural implications. 
Recently a particular UCB banking model has been descried that challenges this 
dual opposition, namely hybrid UCB banking. Hybrid banking models is an umbrella 
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term for banking practices that show a participation of private UCB banks in the public 
redistributive economy. The emergence of such business practices has attracted the atten-
tion of scholars, both in the field of medical ethics (O’Connor et al. 2012), and in Science 
and Technology Studies (STS), because it highlights the “fluid boundaries separating sec-
tors” (Martin et al. 2008, 132).  
Building on STS literature on the wider bioeconomy and UCB banking, we criti-
cally examine the involvement of different economies in the two seemingly separate in-
stitutional arrangements. Thereby we do not wish to negate that crucial differences exist 
between the public and private sector in UCB banking. However, we argue that the op-
position between bioeconomies is less one of institutional arrangements in tissue banks 
but how banking practices do or do not commodify UCBs and thus support different 
forms of capital and moral value investment into the tissues. This article adopts the per-
spective of bioeconomic analysis. Bioeconomy refers to how biological materials (or-
gans, tissues, cells, and gene sequences) “are increasingly inserted into projects of prod-
uct-making and profit-seeking” (Helmreich 2008: 464). A more general definition by the 
Organization for Economic Cooperation and Development (OECD) designates bioecon-
omy as the “… set of economic operations in a society that use the latent value incumbent 
in biological products and processes to capture new growth and welfare benefits for citi-
zens and nations” (OECD 2006; 1). This definition acknowledges that bioeconomy is not 
a concept limited to a capitalist market economy. It invites exploration of the different 
socio-economic systems of production, circulation and exchange, their structure and also 
their societal implications. A fundamental notion for such an analysis is “biovalue”. Cath-
erine Waldby has defined biovalue as “the yield of vitality produced by the biotechnical 
reformulation of living processes” (Waldby 2002, 310).  
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We use the notion ‘hybrid banking models’ when referring to the emerging liter-
ature and introduce the expression ‘hybrid banking practices’ when analysing the con-
crete effects of hybrid or cross-sector engagements between the public and the private 
UCB banking services. We point that in cord blood economy the notion of hybridity does 
not refer exclusively to particular banking models, but to a set of practices. Focussing on 
banking practices instead of institutional arrangements allows exploring different regimes 
of biovalue exploitation that may or may no longer fit the simple and static opposition 
between a public and a private sector. In particular, we focus on how hybrid banking 
practices redefine notions of de- and commodification and thus how these banking prac-
tices decouple the equations public = redistributive and private = market economy. In 
order to make this argument, we draw on two different understandings of de- and com-
modification. One is commonly found in the STS literature on bioeconomies; there com-
modification refers to the transformation of body parts into objects that can be exchanged 
and capitalised. The other has been developed in social science studies of welfare sys-
tems. There commodification and de-commodification refer to the role of the market in 
the provision of social and healthcare services. Adopting a bioeconomy perspective, we 
show in the next section that the issue of whether or not tissues are commodified are more 
complex than the bioethical, biomedical and STS literatures suggest when they opera-
tionalise the distinction between public and private banks. We demonstrate that commod-
ification takes place also in public UCB banking, and that, contrary to common interpre-
tations, the private sector can be seen as not commodifying UCBs. The UCB banking 
sector is a hybrid of different bioeconomic regimes where redistributive and market econ-
omy (see Hauskeller and Beltrame 2016), commodification and de-commodification pro-
cesses coexist and overlap in complex configurations. We investigate these hybrid prac-
tices both in conventional banking models and, especially, in the so-called hybrid models 
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where the complexity of commodification processes at work is particularly apparent. In 
this analysis we extend the notion of hybridity to practices affecting the whole field of 
cord blood banking, and not only to particular banking models. 
To emphasise our main argument, we adopt the heuristic distinction between a 
regime of truth and a regime of hope (Martin et al. 2008). The public and the private 
sector are involved in different ways in both current haematological applications (regime 
of truth) and in future promises of regenerative medicine (regime of hope). On the one 
hand, this rethinking of the truth-hope distinction serves us to stress how untenable the 
simple public and private opposition is for capturing current biomedical uses of human 
tissues. On the other hand, we conclude that hybrid banking practices blur the boundaries 
between public and private sectors as the literature states, but they moreover relocate 
differences in the ways in which human tissues are commodified or not. 
 
Methods 
This article is a critical reflection on UCB banking practices, especially hybrid practices, 
and their implications. We talk about hybrid banking practices since the commonly used 
expression “hybrid banking models” takes implicitly the perspective of a basic and static 
private-public division of institutional arrangements and forms of business organization. 
It thus conceptually precludes the relevancy of the hybrid phenomena and with that the 
systematic critique of the bioeconomic implications and societal effects of current bank-
ing practices. These we aim to analyse here. Focusing on banking practices we can ana-
lyse the concrete entanglement between public and private banking arrangements and 
between redistributive and market economies involved. Hybrid UCB banking models are 
in most cases ways in which private banks manage special banking programmes within 
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their range of conventional commercial services. Shifting the analysis from banking mod-
els to these concrete practices opens up a conceptual space to consider their bioeconomic 
implications. 
This critical analysis of hybrid banking practices draws on the STS literature on 
UCB bioeconomies and on the secondary analysis of our empirical fieldwork in the UCB 
banking sector. Since 1998 Christine Hauskeller has been conducting research on stem 
cell scientific practices, including an empirical study on cord blood banking with field-
work observation and interviews with women and professionals at obstetric and child 
leukaemia clinics, and staff at private and public UCB banks in Germany in 2001/2002. 
Since 2013, Lorenzo Beltrame has been conducting extensive systematic document anal-
ysis of the literature on UCB banking and documents produced by both institutions oper-
ating in the UCB sector (Bone Marrow Donors Worldwide, Eurocord, NetCord) and bi-
oethical and medical professional advisory bodies (American Academy of Pediatrics, 
1999; Royal College of Obstetricians and Gynaecologists, 2006; European Group on Eth-
ics in Science and New Technologies, 2004; ACOG Committee on Obstetric Practice, 
2008). 
In this article we examine the implications of UCB banking practices building on 
a review of the previously published research material. We do not present new empirical 
research findings but our reflection on the implications of hybrid banking practices in 
light of the STS literature and our previous research findings.  
 
The bioeconomy of UCB banking and clinical application 
Public and private UCB banks are motivated by different medical rationalities. Public 
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banks manage the collection of voluntarily donated UCB units for use in current haema-
tological and oncological therapies, mainly in unrelated allogeneic settings. By contrast, 
private banks promote UCB banking for autologous or family use. The underwriting med-
ical rationalisations for this private service are that the rate of success in UCB transplan-
tation rises in family-related settings1 (Hollands and Mccauley 2009), and that the pri-
vately owned UCB account reduces the time and the risks associated with the search for 
compatible UCB units. Moreover, private storage is advertised with an emphasis on the 
future development of biomedicine. Private banks’ advertising cites research and clinical 
trials using UCB-derived stem cells (Bardelli 2010) for treating cardiac and neurological 
diseases, and the discovery of mesenchymal and other pluripotent stem cells in placenta 
and in the umbilical cord tissue (Hollands and Mccauley 2009). Private banking locates 
itself as part of the emerging sector of personal regenerative medicine and novel stem 
cell-based cures. 
Martin and colleagues have described these opposing medical rationalities with 
the heuristic distinction between a “regime of truth” and a “regime of hope” (2008). The 
former is based on “current present-oriented ‘evidence-based’ support for existing appli-
cations of CB stem cells” (p. 136); the latter is oriented toward future stem cell therapies. 
According to them public banks operate only in the regime of truth, whereas private banks 
relate their services to both the regime of truth and the regime of hope. This distinction 
can be made relevant for studies of the bioeconomic and social implications of UCB 
banking, and for analyses of concrete banking practices, especially an understanding of 
deviations from the public-private distinction in hybrid banking models. 
The dominant bioethical and biomedical discourse associates the “redistributive 
tissue economy” (Santoro 2009) of public UCB banking with particular ethical and social 
values and sentiments of belonging to a national community (Santoro 2011; Beltrame 
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2014). As Waldby noted, public UCB banking evolved using the established blood ser-
vices as its logistic basis. It thus also claimed the blood service’s moral justification, sys-
tematized famously by Richard Titmuss The Gift Relationship (1970). Voluntary tissue 
donation would promote both civil inclusion in the polity and “the redistributive ethics of 
the welfare state” (Waldby 2006, 57). To confirm this, we mention as an example that the 
European Group on Ethics in Science and New Technologies (EGE) stated in Ethical 
aspects of umbilical cord blood banking (EGE 2004, 18) that public UCB banking “im-
plies an act of solidarity or generosity [and] contributes to the social cohesion”. Medical 
ethicists define donation as “altruistic”, “philanthropic” and as promoting “the common 
good” (Sugarman et al. 1995; Annas 1999).  
In stark contrast, private banking is criticized as “running for profit” and as selling 
“a service, which has presently, no real use regarding therapeutic options” and promising 
“more than they can deliver” (EGE 2004, 20). In the bioethical and biomedical literature 
generally, private banking is associated with a negative image of commercialization in 
biomedicine that exploits the emotional vulnerability of new and prospective parents, 
commodifies human body parts and damages the public health sector by diverting re-
sources and reducing the pool of donors (the American Academy of Paediatrics 1999; 
Royal College of Obstetrician and Gynaecologist 2006; ACOG Committee on Obstetric 
Practice 2008). Private banking is depicted as a service within the market economy that 
drives to capitalize and commodify tissues based on “self-interest” and “individual ben-
efits” (Ecker and Green 2005). In other words, the private sector is seen as substituting 
valued social relations of civic inclusion with individualist values and profits in emerging 
tissue markets. 
We have called this framing of the UCB banking economy “narrative of opposi-
tion” (Hauskeller and Beltrame 2016) since it is based on a set of juxtapositions that create 
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a rigid divide between the public and the private UCB banking sectors. The narrative of 
opposition is a discourse – that is a practice that forms the objects of which it speaks 
(Foucault 1972, 64). This discourse structures ‘areas of knowledge and social practice’ 
and ‘social entities and relations’ (Fairclough 1992, 3). It constitutes what has been called 
a hegemonic model or paradigm of medical innovation (Salter et al. 2015). The paradigm 
model is a linear innovation process that progresses from basic research via clinical ex-
perimentation, product development, clinical trials and product approval to clinical ap-
plications. This path of innovation aims at the parallel advancement of both generalizable 
knowledge and proven, safe clinical application (pp. 156-157). It gains hegemony 
through the alliance between ‘science, medicine and industry’ that propagate it and the 
set of ‘national and transnational institutions of governance that protect it’ (p. 157). Fi-
nally, Salter and colleagues point out that official bioethical institutions – bioethicists as 
‘experts in legitimizations’ – provide the normative and ideological justification for this 
model pathway.  
In a similar fashion the narrative of opposition has been adopted by biomedical 
experts in relation to UCB banking, science and clinical application, (e.g. Gluckman 
2000) and institutions governing the field (e.g. Bone Marrow Donors Worldwide, Euro-
pean Group for Blood and Marrow Transplantation, Eurocord, NetCord, the U.S. Na-
tional Marrow Donor Program). It is being propagated by medical organizations (e.g. the 
American Academy of Paediatrics 1999; Royal College of Obstetrician and Gynaecol-
ogist 2006; ACOG Committee on Obstetric Practice 2008) and legitimized by bioethicists 
(e.g. Sugarman et al. 1995; Annas 1999) and the policy advice documents of bioethical 
institutions (e.g. Comitè Consultatif National d’Ethique 2002; EGE 2004). Salter and col-
leagues (2015, 157), adopting Gramsci’s terminology, define blocco storico (historical 
block) the alliance of social forces that sustains the process of hegemony. In the case of 
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UCB banking, the narrative of opposition is the legitimizing discourse of the above de-
scribed set of professional and institutional actors who perform as an “epistemic commu-
nity”. An epistemic community has been defined as “a network of professionals with 
recognised expertise and competence in a particular domain and an authoritative claim to 
policy relevant knowledge within that domain or issue-area” (Haas 1992, 3) that aims to 
influence national and international regulations according to the biomedical and ethical 
logic underpinning the public system of UCB banking and clinical application.2   
The narrative of opposition is profoundly inspired by Titmuss’ The Gift Relation-
ship with its accent on the moral primacy of voluntary donation, its call to social solidar-
ity, cohesion and community bonds. Similarly to the criticism that economist Kenneth 
Arrow brought forth against Titmuss, calling this narrative “a passionately informed com-
mitment to an ideal social order” (Arrow 1972, 360, quoted in Steiner 2003, 149) we 
judge it inadequate concerning its understanding of how the economic mechanisms oper-
ate and are mixed up. Also, from the point of view of social sciences’ and STS analyses 
of the wider bioeconomy, the opposition narrative of the public-private distinction is un-
tenable. It does not provide an adequate account of the concrete socio-economic systems 
of circulation, exchange and production of biovalue in UCB banking.  
Whilst dealing with the increasing commercialization and capitalization in the life 
sciences and biomedical sectors, STS scholars have explored the concrete structuring and 
the articulations of different regimes of biovalue exploitation beyond the static categories 
of redistributive and market economy to fixed institutional sectors. Biotechnologies ex-
tract a surplus value from biological fragments which are then capitalized through their 
mobilization in circuits of exchange, patenting and/or licensing in a regime of intellectual 
property rights and in speculative stock market investments (Waldby 2002; Sunder Rajan 
2006; Cooper 2008). This implies socio-economic dynamics that are more complex than 
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the thesis of de-humanizing commodification of body parts in a pure market economy 
suggests (Andrews and Nelkin, 2001). As Sunder Rajan (2003, 87) noted, biocapitalism 
operates through “shifting and variable use of market commodification versus public 
commons or public goods formation” and therefore market logic “is often most at stake 
in the strategic articulations of biocapitalism” (p. 93). At the same time, the circulation 
of these body fragments takes place in complex bioeconomies. The adoption of market 
forms does not necessarily imply the severing of social ties, but creates new kinds of 
relationships (Waldby 2002).  
 
Commodifying tissues or services? Introducing concepts from social welfare 
studies  
In what follows, we show how STS analyses of the UCB bioeconomy can be mobilized 
to challenge the dominant narrative of opposition, by showing how the two main sectors 
cannot be simplistically encapsulated into rigid distinction of redistributive versus mar-
ket economy, commodification versus de-commodification and regime of truth versus 
regime of hope. On the contrary, UCB circulates in hybrid configurations blurring the 
boundaries between institutional arrangements and traditional UCB economies 
(Hauskeller and Beltrame 2016). This emerging hybridity reflects not only on the cul-
tural, ethical and biopolitical implications of the different UCB bioeconomies, but also 
on the implications of what scholars call hybrid banking models.   
Private UCB banking is a paradigmatic case to study the complexities of emerging 
bioeconomies. Its forms of biovalue cannot easily be reduced to a simple notion of com-
modification. Private banking is legitimised through a promissory discourse rotating 
around notions of “investment” and “biological insurance” (Waldby 2006). Through pri-
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vate banking, UCB becomes “a form of property whose value is oriented toward the bio-
logical future” (Waldby and Mitchell 2006, 125), including both possible future diseases 
and a future regenerative medicine. It has been shown that the personal or family account 
severs the question of property from that of commodification (Waldby 2006; Waldby and 
Mitchell 2006).  
This future-oriented value of UCB would be lost if exchanged as a commodity in 
market transactions. In fact, in the logic of private banking, UCB is an asset not a com-
modity, because a commodity acquires its value in exchange, while an asset has value 
also as property (Birch and Tyfield 2012, 302). In this sense, Fannin (2011) has suggested 
that private stem cell banking is less about the calculative rationality of investment and 
more about the economic practice of “hoarding”. Investment implies the circulation of 
commodities and resources in order to increase their value through transactions. UCB in 
private accounts is hoarded, set aside from circulation, waiting for a future in which its 
regenerative potential will be more developed and its value increased. 
The absence of a direct commodification of privately stored UCB does not mean 
that other forms of commodification and/or capitalization are not in operation. Private 
banks capitalize on selling a service of proprietary control on a biological asset. The mar-
ket of private banking is a market of storing services, not a market of exchanged com-
modities.  
At this point, the notion of commodification as it is employed in social science 
studies of welfare systems (Esping-Andersen 1990) adds valuable insight. From this per-
spective, private UCB banking commodifies a biological service, the provision of which 
relies on the market, and access to it depends on the market performance of individuals: 
… decommodification refers to the extent to which an individual’s access to health 
care is dependent upon their market position and the extent to which a country’s 
provision of health is independent from the market (Bambra, 2005, 201). 
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From this perspective, private banking is associated in the literature with “neoliberal 
forms of health entrepreneurship” (Waldby 2006, 59) involving novel forms of “neolib-
eral medical subjectivity” (ibid. p. 67) and “biological citizenship” (Rose and Novas 
2005). These bioeconomic notions present the individual as managing her own health (or 
that of her family members) by negotiating in a market of biological services (Santoro 
2011; Fannin 2013; Beltrame 2014).  
This privatised market does not take place in a void of social relationships – as 
bioethical and medical professional bodies seem to suggest. Private UCB banking estab-
lishes a link between good parenting and biomedicine. Since kinship duties and family 
ties are involved in private and family UCB banking. The industry of commercial UCB 
banks capitalizes on aspirational emotions, affectivity, and future health risks (Brown and 
Kraft 2006, 316). But while bioethical and medical bodies see this as an exploitation of 
the emotional vulnerability of parents (American Academy of Pediatrics 1999), Brown 
and Kraft stress what they call a “techno-moral entry point” in the articulation of parent-
ing and kinship responsibility (2006, 325). Looking after the future health of the family 
might entail responsibly reflecting on how the UCB should be used.  
 
Commodification in the public banking sector 
The commodification versus decommodification conundrum also affects public UCB 
banking. The ideal of a gift-redistributive economy that refutes any logic of economic 
profit is called into question by analyses of the bioeconomic practices public banks en-
gage in. Defining UCB as medical waste if it remains outside the UBC economy imposes 
the “moral junction not to squander something potentially precious” (Brown 2013, 98) 
and attaches a value to the tissue that enables its economic exploitation. Practices related 
to cord blood and human placenta have a long and complex genealogy (Santoro 2011). 
Confidential	Author	Version	–	Pre-proof		
	 14	
Before the discovery of stem cell in UCB, this tissue was used for epidemiological re-
search and sold to cosmetic industries (Waldby and Mitchell 2006). But UCB could be 
capitalized also in other processes of commodification. In an interview study from 2001, 
Hauskeller and Manzei found that public UCB biobanks released and sold discarded UCB 
samples to research groups and biotech companies for a surplus (Hauskeller 2002; 2005; 
Manzei 2005). Manzei has shown, moreover, how public banks in Germany are run by 
private companies or closely connected with University spin-offs involved in developing 
medical innovations from UCB, concluding that “public banks also place the marketabil-
ity of stem cell preparations at the centre of their activity” (Manzei 2005, 58, translation 
CH). In other words, public banks, too, are part of the value production and exchange 
system that exploits the biovalue of UCB for the future development of regenerative med-
icine and stem cell therapies.  
These points illustrate that processes of commodification take place in public 
UCB banking. Even if the bioethical and biomedical discourses link public UCB banking 
to a redistributive economy committed to the shared future of a national community, pub-
lic banks’ repositories are connected worldwide through international registries, in which 
the UCBs are traded and service costs added to be paid for by the buyer. The international 
exchange serves to facilitate the search for compatible UCB units that is necessary to 
secure best clinical outcome because of the different human leucocyte antigen (HLA) 
phenotypes. UCB and its HLA-typisation thus enters the flow of the globalised “econo-
mies of signs and spaces” that reconstitute communities and subjectivities and open up 
possibilities for the heterogenization of space (Lash and Urry 1994, 3). Accordingly, pub-
lic banks do not simply operate within the limits of the nation state. Through international 
registries, computer databases and search engines, HLA-typisation of the UCB allows the 
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transnational flow and the global circulation of UCB units, too (Beltrame 2014, 78). Re-
distribution of UCBs for transplantations thus takes place on an international scale, be-
yond the limits of national or local political community organisations in which the dom-
inant bioethics discourse encloses it. This redefinition of the space has relevant bioeco-
nomic implications. Brown and colleagues (2011, 1115) have explored how the global 
circulation of UCB is implicated in a “capitalisation of immunity” where this tissue be-
comes a sort of currency in an international economy. Within and across the health care 
economy, UCB units are exchanged at a price greater than the cost of collection, pro-
cessing and storage, which generates income for public banks. The global redistributive 
economy of UCB operates through a market model, where “public banks compete for 
advantage in an international marketplace that places a premium” on being able to capi-
talise on quality UCB units for transplantations (Brown 2013, 99). The marketability of 
UCB today and internationally confirms what Hauskeller (2005) and Manzei’s (2005) 
found in their Germany-based study. 
This does not mean that the international circulation is aimed at profit making. As 
Hoeyer (2009) has shown, the moral ideal of keeping the human body apart from trade 
formatted a particular kind of market, where pricing strategies are described as following 
a logic of “compensation of expenses”. However, even if the notion of commodification 
of the UCB is refuted, body parts circulate as commodities in a system of exchange that 
produces both prices and profits. Because a commodity is defined by being bought and 
sold, it would seem that in the public banking system UCBs are commodified. More con-
cretely and presently so than may be the case in private UCB banking, where UCB is a 
speculative asset with potentially rising future value. 
As noted by Waldby (2002), the ideal gift-redistributive economy posited by Tit-
muss (1970) – and adopted in the bioethical and biomedical account of UCB banking – 
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no longer describes the complex bioeconomies involved in the circulation of human tis-
sues. We do not doubt the existence of important differences between public and private 
UCB banking and their societal and cultural implications. However, static economic cat-
egories seem less and less analytically useful when mapping the redistributive and market 
dynamics involved in UCB economies. Similarly, labelling whole institutional sectors as 
either inspired by ethical considerations of sharing or by economic profit-seeking reasons 
does not enable a good understanding of the societal effects of UCB banking models. We 
argue that it is time to decouple the equations public = redistributive economy and private 
= market economy. Our systematic analysis of the concrete practices of UCB banking 
shows an interlocking and entanglement between and across economic regimes and insti-
tutional sectors. Below, we explore hybrid banking models, and introduce and build on 
the concepts of commodification and de-commodification as developed in welfare system 
analyses to discuss some implications of hybrid practices in UCB bioeconomies and what 
they mean. 
The challenge of hybrid UCB banking practices to de-commodification 
Hybrid UCB banking models are considered the main biomedical space in which the pub-
lic-private distinction has previously been challenged. In this context, the term hybrid 
indicates an array of UCB banking practices in which private banks make UCB units 
available to public healthcare institutions. Through these hybrid practices, private banks 
contribute to the redistribution of the human tissue for transplantation in public healthcare 
institutions. In other words, hybrid models are nothing but UCB banking practices usually 
located in the realm of public banks – according to the established public-private distinc-
tion – but actually undertaken by private and commercial UCB banks. This contribution 
to the public sector is included in the business of private banks, and it is motivated either 
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by ethical or marketing intention or, in other cases, is instigated by local regulatory con-
ditions of UCB banking operation. 
We list the major hybrid practices here. The most established form are donation 
programs and dedicated family storage for families at special health risk managed by 
private banks and without charge at the point of UCB collection (Wolf 1998). A second 
type of hybrid banking models is promoted by national laws (e.g. in Turkey and Spain) 
that stipulate that private banks make available part of their repository to the public 
healthcare systems (O’Connor et al. 2012). A third form has been developed by the UK’s 
Virgin Health Bank, where each stored UCB sample is split: 20% of the sample is stored 
for private use and 80% for public use (Lancet 2007; Martin et al. 2008). Finally, the most 
interesting form of hybrid practice for our argument is “donatable family banking”, de-
scribed by Hung-Chieh Chang (2014). Parents pay a fee for private storage in a UCB 
bank, but the UCB unit is made available for search in the international UCB transplant 
registries. Should the UCB unit be flagged as HLA-matching for a particular patient, the 
customers of the private bank and owners of the UCB can decide whether they want to 
keep it, sell it, or donate it for the treatment of this patient.  
According to O’Connor and colleagues (2012), the emergence of hybrid banking 
models reflects the influence of both market forces and public sector policies. In face of 
restrictive regulations that prohibit private banking in some countries, offering privately 
stored UCB as potentially available in the public system is a strategic move to “weaken 
the warrant for legislation or regulatory controls” limiting or hampering the business of 
private UCB banks (p. 515). However, these hybrid practices are economically profitable. 
They entail new articulations of the market logic, which shift the relation between market 
commodification and public commons (Sunder Rajan 2003, 87) that structures the dis-
tinction between a public and a private sector.  
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Hybrid models capture the active participation of private banks in the public re-
distributive UCB economy. Private banks perform functions that would be carried out by 
the public UCB banking system only, according to the opposition narrative. Therefore, 
the dynamic de- and commodification in the healthcare service of UCB banking and clin-
ical application cannot be captured in terms of an opposition between a public and a pri-
vate sector. Our analysis of hybrid practices enables looking afresh at the established 
notions of de- and commodification, which reveals some paradoxical implications. Usu-
ally, private banking offers a health service in a market framework, that is, it commodifies 
a healthcare service: 
… the larger the size of the private health sector, in terms of expenditure and con-
sumption, the larger the role of the market and therefore the lower the degree of 
health decommodification (Bambra 2005, 202) 
The participation of private UCB banks in the redistributive economy through hybrid 
practices undermines the suggested equation of private sector banking with commodifi-
cation. Donation programmes and/or the part of repositories made accessible for a public 
healthcare system represent a de-commodification of the UCB storage service. Hybrid 
practices, thus, also mean that the size of the private sector in UCB banking is not a reli-
able index of health commodification.  
Nevertheless, this de-commodification of the storage service corresponds to pro-
cesses of commodification and capitalization of the value of the tissue itself. Making 
available part of their repositories for use by public services, hybrid banking practices 
participate in the international exchange of UCB units. Thus, private banks, too, can cap-
italize on export prices that exceed the cost of the storage service. The charge for an 
exported UCB unit can exceed €20.000, while a service of 20 years of storage is usually 
offered at around €3000 (Vita34 2015b). Thus, if a donated UCB is sold, the revenue is 
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higher than the profit from private storage. While in the private account UCB is kept apart 
from circulation, hybrid practices turn the UCB into a tradable object, a commodity cir-
culating in an international market. What seems an ethical commitment to the moral re-
distributive economy instead follows the logic of this particular market economy.  
This dynamic gains a new and hitherto not described feature in the case of “dona-
table family banking” (Chang 2014). In this setting, the account holder ultimately decides 
whether the privately stored UCB will remain a private asset or become a commodity 
sold for revenue or a resource donated for the public good. Donatable family banking re-
draws the boundaries between the good citizen and the neoliberal health entrepreneur as 
enacted in the parental decision whether to store or donate UCB at birth. 
Applying the distinction between a regime of truth and a regime of hope, hybrid 
banking practices not only blur the boundaries between the private and the public, they 
restructure and relocate these boundaries. While public banks operate mainly in a regime 
of truth – using stored tissues for currently required therapeutic interventions – private 
banks “relate their services to both current applications and the future potential of regen-
erative medicine” (i.e. regime of hope, Martin et al. 2008, 140). Hybrid banking practices 
seem to thoroughly conflate the two regimes, first, because they operate simultaneously 
in the sector of public redistributive UCB economy and in the market of private services, 
and secondly because they are involved in current clinical treatments and also nurture and 
economise on the future promise of regenerative medicine. If we look at banking practices 
and their hybrid intersections in the regime of truth, the literature that speaks of a blurred 
boundary between public and private would seem confirmed. 
Moreover, however, while hybrid models as activities of private banks partake in 
the de-commodification of UCB banking services for clinical applications that carry the 
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insignia of the regime of truth – decoupling the public from the monopoly over redistrib-
utive economy – things are different in the regime of hope. The privately marketed per-
sonal UCB account linked to expectations of future developments in stem cell science 
and emerging therapies remains a firm and necessary element in the practice of private 
UCB banking. In this sense, hybrid banking practices accentuate the public-private dis-
tinction in the regime of hope and partake in the commodification of personalised regen-
erative medicine. In other words, on the one hand hybrid practices blur the public-private 
divide in relation to current haematological application, on the other hand, they reaffirm 
and thrive on UCB storage and asset management in view of the promise of a future stem 
cell medicine. 
Conclusions 
In addressing the public-private distinction in UCB bioeconomies, the STS literature has 
offered insights that we have mobilized to problematize the equation that public UCB 
banking operates in a moral economy of redistribution and private UCB banking is a form 
of tissue commodification in a market economy. Following through with these insights 
of STS, our analysis shows how the adoption of static categories – such as private versus 
public, or redistributive versus market economy – does not reflect the complex articula-
tions of different UCB economies. In particular, the equation of public UCB banking with 
an ideal moral gift-redistributive economy that resists the commodification of UCBs is 
problematic. Public banking de-commodifies the provision of UCB for transplants, but 
other forms of commodification of the tissue take place. At the same time, while public 
banks work mainly in the regime of truth of current haematological applications, they are 
also involved in creating and stabilising a global value chain that extrapolates biovalue 
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from UCB as a source of stem cells for future therapies and capitalizes on the commodi-
fication of human tissues. Conversely, while private banks commodify the health service 
of UCB storage, at least for the time being, they actually de-commodify the tissue, turning 
it into a private asset and thus removing it from the current system of circulation and 
exchange. The UCB’s value is created there as a prospective, future value. 
Our analysis of commodification processes in hybrid banking practices shows that 
the public and the private sector, the redistributive and the market economy, are inter-
locked and entangled. Yet, this process is more complex than just a blurring the boundary 
between public and private banking and confusion of the related alignments to forms of 
biovalue creation. Hybrid banking practices relocate and restructure these notions. On the 
one hand, indeed, through hybrid banking practices private banks partake in the redistrib-
utive UCB economy and thus contribute to the de-commodification of the UCB banking 
service. On the other hand, this de-commodification of the service implies the commodi-
fication of UCB as material, and this commodification is motivated by a market logic of 
profitability. Donation programs and other free of charge banking options involve the 
circulation of UCB units for clinical interventions that are financially rewarded in the 
international exchange of UCB units. Therefore, while private banks continue to generate 
income from the storage fee in their business of family banking, they also add revenue 
from providing UCBs for transplantations through contributions to the public banking 
services. The participation in the public redistributive UCB economy does not simply 
respond to an ethical commitment on the side of the private banks, it is an articulation of 
the market logic in which they operate. The equation of the public sector with redistribu-
tive economy and the private sector with market economy is decoupled. This analysis of 
an erasure of the private-public distinction, however, applies only in the regime of truth, 
the engagement in current medical practice and treatments.  
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Regarding the hope that future developments in regenerative medicine will add 
value to UCB assets, hybrid UCB banking practices strengthen the public-private distinc-
tion. Private banks adopting hybrid banking practices continue to build a great part of 
their business on the income generated by the UCB storage fee, which, in turn, is moti-
vated by the expectation of a future medical value of this human tissue for regenerative 
medicine. This expected future value transforms UCB into a speculative asset and thus 
increases the commodification of UCB storage service in the private sector. The public 
UCB banking sector, indeed, is not directly involved in this orientation toward a (medical 
and economic) future, and hybrid banking practices do not intertwine the public and the 
private sector in the regime of hope. In other words, in the case of hybrid banking prac-
tices, too, the provision of UCB storage for possible future regenerative medicine is de-
pendent on the market in the same way in which individuals’ access to this health service 
is dependent upon their market position.  
In its opinion on UCB banking the European Group on Ethics (EGE 2004) stated 
that “if in the future regenerative medicine developed in such a way that using autologous 
stem cells became possible… Not everyone may be able to afford the costs of storage. In 
that case, access would be related to financial resources” (p. 19). EGE added that, if such 
developments occurred “the storage should not be a service left to commercial banks but 
should be taken over by the public sector in order to ensure fair access to healthcare ser-
vices for everybody” (p. 22).  
We interpret the ethical perspective represented here with the influential statement 
by the EGE, as indicating that hybrid practices do not address or solve issues of social 
justice and fairness of access to biomedical technologies and services. Instead, they move 
these societal issues from the present to the future, from the field of current haematolog-
ical application into the hypothetical realm of future cures and applications of stem cells 
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in the clinic. Hybrid banking practices bring private banks into the public redistributive 
tissue economy, thus de-commodifying the provision of a healthcare service. But, at the 
same time, private banks continue to capitalize on future developments in regenerative 
medicine by selling proprietary control over the UCB as a private asset.  
We conclude therefore that the ways in which hybrid UCB banking practices are 
blurring the boundaries between public and private are more complicated than described 
in the bioethics literature. The dominant narrative describes a social order founded on 
solidarity and cohesion, supported by a redistributive tissue economy and threatened by 
the spread of a commodifying market economy. The presence of hybrid banking practices 
undermines this view; processes of commodification – those affecting public banking and 
those involved in hybrid banking models – show that this order is more alleged and 
deemed desirable than real. Moreover, hybrid practices trouble and destabilise the order 
in which future medical therapies based on novel uses of human tissues are conceived in 
expert and lay communities. In this sense, the term hybrid expresses the ethical concern 
regarding the transition between the public redistributive and the private market economic 
sphere. A transition that is already permeating the whole cord blood bioeconomy and that 
makes the opposition narrative untenable for descriptive and analytical purposes. At the 
same time, however, considering the future of tissue banking and regenerative medicine, 
the term hybrid still entails the original opposition of economic models and their ethical 
and societal implications. The use of the term hybrid thus expresses a biopolitical com-
mitment to equality in health care that underlies the opposition narrative.  
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1 UCB can be used in different ways in clinical applications: transplantations from donor to biologically 
unrelated recipient are called unrelated allogeneic; transplantations between siblings or family members, 
related-allogeneic; and transplantations where donor and recipient are the same person, autologous.   
2 The role of this set of actors in influencing national and international regulations could be attested through 
some examples. For example, Eurocord member Manuel Fernandez, in an article reporting the Eurocord 
position on ethical and legal issues in UCB banking, stated: “Regulations or legislations to be enforced by 
governments or international organizations should be previously advised and audited by the international 
community of scientists experienced in CBT. Eurocord group… regards itself as an adequate body to fulfil 
this role” (1998, S85). Eliane Gluckman was heard as expert both by the French Comité Consultatif Na-
tional d’Ethique (2002; 2012) and by EGE (2004) – and the Comité Consultatif National d’Ethique recom-
mended decision makers of not “subscribing to the creation of private banks” (2002, 10). In Italy, the reg-
ulation prohibiting the establishment of private banks was issued by the then Health Minister Girolamo 
Sirchia, member of Eurocord and founder of the Milan Cord Blood Banks (Repubblica Italiana - Ministero 
della Salute 2002). On the role of EGE, and in particular of its opinion on UCB banking, for European 
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